Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298434 · ClinicalTrials.gov registry record · Phase 3
Study of VYD2311 for the Prevention of COVID-19
A Phase 3 study of COVID-19, sponsored by Invivyd.
- Active
- Registry status
- Phase 3
- Development phase
- 1,770
- Enrollment target
- 20
- Study locations
NCT07298434 is a Phase 3 study of COVID-19 that is active but no longer recruiting, run by Invivyd. The registered enrollment target is 1,770 participants, below the 55,206-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT07298434, a Phase 3 study of COVID-19, is active but no longer recruiting, sponsored by Invivyd.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,770 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VYD2311-SD
- DRUG VYD2311-MD
Study Locations (20)
Texas
- Invivyd Investigative Site - Houston
- Invivyd Investigative Site - Houston-2
- Invivyd Investigative Site - Irving
- Invivyd Investigative Site - Sugar Land
California
- Invivyd Investigative Site - Long Beach
- Inviviyd Investigative Site - San Diego
Florida
- Invivyd Investigative Site - Orlando
Georgia
- Invivyd Investigative Site - Hinesville
Illinois
- Invivyd Investigative Site - Melrose Park
Kansas
- Invivyd Investigative Site - Lenexa
Maryland
- Invivyd Investigative Site - Silver Spring
Massachusetts
- Invivyd Investigative Site - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,770 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298434
The ClinicalTrials.gov registry entry for NCT07298434 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,770 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,206-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The listed sponsor is Invivyd, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07298434 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07298434 about?
NCT07298434 is a clinical study titled "Study of VYD2311 for the Prevention of COVID-19". The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adul...
What is the current status of trial NCT07298434?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,770 participants. The study started on 2026-01-08. Estimated completion is 2026-06.
What conditions does trial NCT07298434 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07298434?
The interventions under investigation include: Placebo (DRUG), VYD2311-SD (DRUG), VYD2311-MD (DRUG).
Who is sponsoring clinical trial NCT07298434?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07298434 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.